Reed Douglas MD

CIK 00012912625 companiesMALVERN, PA

SEC Profile

Transactions

Companies

Filings

CIK

0001291262

Recent Transactions

50 trades

Conversion
PhaseBio Pharmaceuticals Inc
Series C-1 Preferred Stock
2018-10-22−40,420→ 0 total
Exercise of In-Money
PhaseBio Pharmaceuticals Inc
Warrants to Purchase Series C-1 Preferred Stock
2018-10-22−47,458→ 0 total
Exercise of In-Money
PhaseBio Pharmaceuticals Inc
Warrants to Purchase Series C-1 Preferred Stock
2018-10-22−4,309→ 0 total
Conversion
PhaseBio Pharmaceuticals Inc
Series 1 Preferred Stock
2018-10-22−4,846→ 0 total
Conversion
PhaseBio Pharmaceuticals Inc
Series AA Preferred Stock
2018-10-22−13,609→ 0 total
Conversion
PhaseBio Pharmaceuticals Inc
Series B Preferred Stock
2018-10-22−94,874→ 0 total
Conversion
PhaseBio Pharmaceuticals Inc
Series C-1 Preferred Stock
2018-10-22−149,320→ 0 total
Conversion
PhaseBio Pharmaceuticals Inc
Common Stock
2018-10-22+1,683,420→ 1,683,420 total
Conversion
PhaseBio Pharmaceuticals Inc
Common Stock
2018-10-22+52,690→ 52,690 total
Conversion
PhaseBio Pharmaceuticals Inc
Common Stock
2018-10-22+266,481→ 266,481 total
Conversion
PhaseBio Pharmaceuticals Inc
Series D Preferred Stock
2018-10-22−272,107→ 0 total
Exercise of In-Money
PhaseBio Pharmaceuticals Inc
Series B Preferred Stock
2018-10-22$0.12/sh+19,061→ 1,045,222 total
Exercise of In-Money
PhaseBio Pharmaceuticals Inc
Warrants to Purchase Series B Preferred Stock
2018-10-22−1,731→ 0 total
Sale
PhaseBio Pharmaceuticals Inc
Series B Preferred Stock
2018-10-22$5.00/sh−42→ 94,874 total
Exercise of In-Money
PhaseBio Pharmaceuticals Inc
Warrants to Purchase Series C-1 Preferred Stock
2018-10-22−41,414→ 0 total
Sale
PhaseBio Pharmaceuticals Inc
Series C-1 Preferred Stock
2018-10-22$5.00/sh−994→ 40,420 total
Conversion
PhaseBio Pharmaceuticals Inc
Series 1 Preferred Stock
2018-10-22−3,862→ 0 total
Conversion
PhaseBio Pharmaceuticals Inc
Series B Preferred Stock
2018-10-22−1,044,764→ 0 total
Purchase
PhaseBio Pharmaceuticals Inc
Common Stock
2018-10-22$5.00/sh+137,513→ 1,820,933 total
Sale
PhaseBio Pharmaceuticals Inc
Series C-1 Preferred Stock
2018-10-22$5.00/sh−1,139→ 149,320 total
Exercise of In-Money
PhaseBio Pharmaceuticals Inc
Series C-1 Preferred Stock
2018-10-22$0.12/sh+4,309→ 13,662 total
Sale
PhaseBio Pharmaceuticals Inc
Series C-1 Preferred Stock
2018-10-22$5.00/sh−104→ 13,558 total
Conversion
PhaseBio Pharmaceuticals Inc
Series 1 Preferred Stock
2018-10-22−52,690→ 0 total
Conversion
PhaseBio Pharmaceuticals Inc
Series D Preferred Stock
2018-10-22−226,061→ 0 total
Conversion
PhaseBio Pharmaceuticals Inc
Common Stock
2018-10-22+150,612→ 150,612 total
Conversion
PhaseBio Pharmaceuticals Inc
Common Stock
2018-10-22+4,846→ 4,846 total
Exercise of In-Money
PhaseBio Pharmaceuticals Inc
Series C-1 Preferred Stock
2018-10-22$0.12/sh+47,458→ 150,459 total
Conversion
PhaseBio Pharmaceuticals Inc
Series 1 Preferred Stock
2018-10-22−42,530→ 0 total
Conversion
PhaseBio Pharmaceuticals Inc
Series C-1 Preferred Stock
2018-10-22−13,558→ 0 total
Purchase
PhaseBio Pharmaceuticals Inc
Common Stock
2018-10-22$5.00/sh+150,000→ 416,481 total
Exercise of In-Money
PhaseBio Pharmaceuticals Inc
Series C-1 Preferred Stock
2018-10-22$0.12/sh+41,414→ 41,414 total
Conversion
PhaseBio Pharmaceuticals Inc
Series AA Preferred Stock
2018-10-22−174,699→ 0 total
Conversion
PhaseBio Pharmaceuticals Inc
Series D Preferred Stock
2018-10-22−24,709→ 0 total
Purchase
PhaseBio Pharmaceuticals Inc
Common Stock
2018-10-22$5.00/sh+12,487→ 163,099 total
Exercise of In-Money
PhaseBio Pharmaceuticals Inc
Warrants to Purchase Series B Preferred Stock
2018-10-22−19,061→ 0 total
Sale
PhaseBio Pharmaceuticals Inc
Series B Preferred Stock
2018-10-22$5.00/sh−458→ 1,044,764 total
Exercise of In-Money
PhaseBio Pharmaceuticals Inc
Series B Preferred Stock
2018-10-22$0.12/sh+1,731→ 94,916 total
Sale
G1 Therapeutics, Inc.
Common Stock
2018-05-30$48.00/sh−41,710→ 3,237,711 total
Sale
G1 Therapeutics, Inc.
Common Stock
2018-05-30$48.00/sh−758,290→ 3,279,421 total
Sale
G1 Therapeutics, Inc.
Common Stock
2018-05-23$50.50/sh−26→ 4,037,711 total
Sale
G1 Therapeutics, Inc.
Common Stock
2018-05-23$50.50/sh−474→ 4,037,737 total
Sale
G1 Therapeutics, Inc.
Common Stock
2018-05-22$50.69/sh−308→ 4,038,211 total
Sale
G1 Therapeutics, Inc.
Common Stock
2018-05-22$50.86/sh−5,592→ 4,038,519 total
Sale
G1 Therapeutics, Inc.
Common Stock
2018-05-21$51.06/sh−1,595→ 4,044,611 total
Sale
G1 Therapeutics, Inc.
Common Stock
2018-05-21$51.16/sh−29,005→ 4,046,206 total
Sale
G1 Therapeutics, Inc.
Common Stock
2018-05-21$52.13/sh−26→ 4,044,111 total
Sale
G1 Therapeutics, Inc.
Common Stock
2018-05-21$52.13/sh−474→ 4,044,137 total
Other
G1 Therapeutics, Inc.
Common Stock
2017-11-30+995→ 4,075,211 total
Other
G1 Therapeutics, Inc.
Common Stock
2017-11-30−99,513→ 4,074,216 total
Conversion
G1 Therapeutics, Inc.
Common Stock
2017-05-22+3,728,464→ 3,728,464 total

Companies

Recent Filings

4
Catalysta Ventures, LLC
Oct 24, 2018

Address

C/O TETRALOGIC PHARMACEUTICALS CORP 343 PHOENIXVILLE PIKE

MALVERN, PA, 19355

View on SEC.gov